CBIO Crescent Biopharma, Inc. - Common Stock
$17,40
Kurs · Aug 19, 2026
Fundamentaldaten per Jul 30, 2026
52W-Spanne
$9–$27
46% of range
Analystenbewertung
BUY
15 analysts
Kursziel
$31
+76% upside
P/E (TTM)
-35.5
ROE
-90.0%
Nettogewinnmarge
-1419.6%
CBIO Aktien-Snapshot Kurs, Marktkapitalisierung, P/E, EPS, ROE, Schulden/Eigenkapital, 52-Wochen-Spanne
Kurs
$17.39
Marktkapitalisierung
$480M
P/E (TTM)
-35.5
EPS (TTM)
$-0.59
Umsatz (TTM)
$11M
Dividendenrendite
—
ROE
-90.0%
Verschuldungsgrad
—
52W-Spanne
$9 – $27
CBIO Aktienkurs-Chart Täglich OHLCV mit technischen Indikatoren — Schwenken, Zoom und Ansicht anpassen
Configure
10-Jahres-Performance Umsatz-, Nettoergebnis-, Margen- und EPS-Trends
Umsatz & Nettoergebnis
$11M
2016-12-31
→
2025-12-31
EPS
$-0.59
2019-12-31
→
2024-12-31
Freier Cashflow
$-72M
2016-12-31
→
2025-12-31
Margen
-1419.6%
Bewertung P/E-, P/S-, P/B-, EV/EBITDA-Verhältnisse — ist die Aktie teuer oder günstig?
Kennzahl
5-Jahres-Trend
CBIO
Peer-Median
P/E (TTM)
-35.5
19.6
P/S (TTM) (K/V (TTM))
44.2
6.4
P/B (K/B)
2.4
2.6
Price / FCF (Kurs / FCF)
-6.6
—
Rentabilität Brutto-, Betriebs- und Nettomargen; ROE, ROA, ROIC
Kennzahl
5-Jahres-Trend
CBIO
Peer-Median
Operating Margin (Betriebsgewinnmarge)
-1407.5%
—
Net Profit Margin (Nettogewinnmarge)
-1419.6%
-104.2%
ROA
-111.6%
-40.3%
ROE
-90.0%
-42.4%
ROIC
-76.2%
—
Finanzielle Gesundheit Verschuldung, Liquidität, Solvenz — Bilanzstärke
Kennzahl
5-Jahres-Trend
CBIO
Peer-Median
Current Ratio (Liquiditätsgrad)
6.6
5.4
Quick Ratio
6.4
—
Wachstum Umsatz-, EPS- und Nettoergebniswachstum: YoY, 3-Jahres-CAGR, 5-Jahres-CAGR
Kennzahl
5-Jahres-Trend
CBIO
Peer-Median
Revenue YoY (Umsatz YoY)
-86.7%
—
Revenue CAGR 3Y (Umsatz CAGR 3J)
424.9%
—
Revenue CAGR 5Y (Umsatz CAGR 5J)
1.3%
—
Kapitaleffizienz Umsatz pro Vermögenswert, Lagerumschlag, Forderungsumschlag
Kennzahl
5-Jahres-Trend
CBIO
Peer-Median
Dividenden Rendite, Ausschüttungsquote, Dividendenhistorie, 5-Jahres-CAGR
Dividendenrendite
—
Ausschüttungsquote
—
5J Div CAGR
—
| Ex-Datum | Betrag |
|---|---|
| 13. Januar 2023 | $24,0000 |
| 21. September 2022 | $143,0000 |
CBIO Analysten-Konsens Bullische und bärische Analystenmeinungen, 12-Monats-Kursziel, Aufwärtspotenzial
KAUF
15 Analysten
- Starker Kauf 6 40,0%
- Kauf 7 46,7%
- Halten 2 13,3%
- Verkauf 0 0,0%
- Starker Verkauf 0 0,0%
12-Monats-Kursziel
5 Analysten · 2026-08-19
Median
$28.00
Mittelwert
$30.60
← Unter allen Zielen
$17.39
Tief
$27.00
Hoch
$35.00
Median-Ziel
$28.00
+61,0%
Mittelwert-Ziel
$30.60
+75,9%
Ergebnisverlauf EPS Ist vs. Schätzung, Überraschung %, Beat-Rate, nächstes Ergebnisdatum
Durchschn. Überraschung
0.18%
| Zeitraum | EPS Actual | EPS est. | Überraschung |
|---|---|---|---|
| 30. Juni 2026 | $-0.74 | $-0.81 | 0.07% |
| 31. März 2026 | $-0.70 | $-0.97 | 0.27% |
| 31. Dezember 2025 | $-0.54 | $-2.57 | 2.0% |
| 30. September 2025 | $-1.27 | $-2.02 | 0.75% |
| 30. Juni 2025 | $-4.93 | $-1.80 | -3.1% |
| 31. März 2025 | $-4.00 | $-5.10 | 1.1% |
Peer-Vergleich (GICS-Subbranche) Wichtige Kennzahlen im Vergleich zu Branchenkollegen
| Ticker | Marktkapitalisierung | P/E | Umsatz Vj. | Nettomarge | ROE | Bruttogewinnmarge |
|---|---|---|---|---|---|---|
| CBIO | $327M | -24.2 | -86.7% | -1419.6% | -90.0% | — |
| ALLO | $314M | -1.6 | -76.8% | — | -59.9% | — |
| GYRE | $645M | 353.0 | 10.2% | 8.5% | 11.7% | — |
| TECX | $391M | -5.2 | — | — | -27.7% | — |
| SGMT | — | -3.7 | — | — | -42.3% | — |
| NVCT | $194M | -5.7 | — | — | -149.9% | — |
| ASMB | $539M | -61.8 | 153.5% | -8.5% | -5.5% | — |
| MDXG | $1.00B | 21.2 | 20.0% | 11.6% | 20.5% | 82.6% |
| SPRY | $1.16B | -6.7 | -5.5% | -203.3% | -111.8% | — |
| ALT | $400M | -3.6 | 105.0% | -214861.0% | -45.6% | — |
Vollständige Fundamentaldaten Alle Kennzahlen nach Jahr — Gewinn- und Verlustrechnung, Bilanz, Cashflow
Gewinn- und Verlustrechnung 14
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $11M | · | $10.0K | $75.0K | $1M | $10M | · | · | · | $18.5K | $20M | $15M | |
| R&D Expense | $138M | $14M | $20M | $28M | $47M | $45M | $47M | $40M | $24M | $23M | $25M | $20M | |
| SG&A Expense | $25M | $18M | $19M | $19M | $17M | $17M | $14M | $11M | $10M | $9M | $8M | $7M | |
| Operating Expenses | $163M | $40M | $39M | $47M | $65M | $62M | $61M | $52M | $34M | $32M | $33M | $26M | |
| Operating Income | $-153M | $-40M | $-39M | $-47M | $-63M | $-52M | $-61M | $-52M | $-34M | $-32M | $-13M | $-11M | |
| Other Non-op | · | $2M | $2M | · | · | · | · | · | $651.2K | $103.6K | $15.3K | $18.2K | |
| Pretax Income | $-152M | · | · | · | · | · | · | · | · | · | · | · | |
| Income Tax | $2M | · | · | · | · | · | · | · | · | · | · | · | |
| Net Income | $-154M | $-38M | $-37M | $-47M | $-63M | $-51M | $-58M | $-48M | $-33M | $-32M | $-13M | $-11M | |
| EPS (Basic) | · | $-0.59 | $-0.58 | $-0.89 | $-1.23 | $-1.12 | $-1.34 | · | · | · | · | $-0.60 | |
| EPS (Diluted) | · | $-0.59 | $-0.58 | $-0.89 | $-1.23 | $-1.12 | $-1.34 | · | · | · | · | $-0.60 | |
| Shares (Basic) | · | 64,477,249 | 63,342,465 | 52,531,173 | 51,453,204 | 45,721,139 | 43,254,782 | · | · | · | · | 18,452,252 | |
| Shares (Diluted) | · | 64,477,249 | 63,342,465 | 52,531,173 | 51,453,204 | 45,721,139 | 43,254,782 | · | · | · | · | 18,452,252 | |
| EBITDA | $-153M | $-40M | $-39M | $-47M | $-63M | $-52M | $-61M | $-52M | $-34M | $-32M | $-13M | $-11M |
Bilanz 21
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $213M | $35M | $42M | $48M | $90M | $137M | $158M | $210M | $124M | $40M | $47M | $55M | |
| Receivables | $18M | $0 | · | · | · | · | · | · | · | · | · | · | |
| Prepaid Expense | $5M | $38.0K | $2M | $3M | $533.8K | $1M | $4M | $2M | $3M | $478.5K | $441.8K | $916.2K | |
| Other Current Assets | $5M | $38.0K | · | · | · | · | · | · | · | · | · | · | |
| Current Assets | $237M | $35M | $44M | $51M | $91M | $138M | $163M | $212M | $127M | $41M | $47M | $56M | |
| PP&E (Net) | $846.0K | $0 | · | $242.4K | $368.8K | $620.7K | $822.9K | $957.2K | $1M | $1M | $521.4K | $452.3K | |
| PP&E (Gross) | · | · | · | $3M | $3M | $3M | $3M | $3M | $2M | $2M | $1M | $1M | |
| Accum. Depreciation | · | · | · | $2M | $2M | $2M | $2M | $2M | $1M | $1M | $902.1K | $905.5K | |
| Other Non-current Assets | $1M | $813.0K | · | · | · | · | · | · | · | · | · | · | |
| Total Assets | $240M | $36M | $45M | $52M | $94M | $143M | $168M | $215M | $129M | $42M | $48M | $57M | |
| Accounts Payable | · | $329.3K | $868.1K | $970.2K | $2M | $2M | $1M | $3M | $3M | $2M | $564.2K | $874.0K | |
| Accrued Liabilities | $16M | $2M | $5M | $7M | $9M | $9M | $9M | $6M | $4M | $3M | $6M | $5M | |
| Current Liabilities | $36M | $10M | $7M | $9M | $12M | $12M | $11M | $9M | $8M | $6M | $8M | $6M | |
| Capital Leases | $1M | $0 | $66.8K | · | $918.6K | $2M | $3M | · | · | · | · | · | |
| Total Liabilities | $37M | $47M | $7M | $9M | $13M | $15M | $14M | $9M | $9M | $7M | $8M | $6M | |
| Common Stock | $28.0K | $1.0K | $64.4K | $54.4K | $52.3K | $49.0K | $43.5K | $43.2K | $34.4K | $23.2K | $19.0K | $18.9K | |
| Paid-in Capital | $371M | $2M | $495M | $462M | $454M | $438M | $413M | $406M | $272M | $154M | $128M | $125M | |
| Retained Earnings | $-172M | $-18M | $-456M | $-420M | $-373M | $-309M | $-258M | $-201M | $-152M | $-119M | $-87M | $-74M | |
| Stockholders' Equity | $203M | $-15M | $38M | $43M | $82M | $128M | $154M | $205M | $120M | $35M | $40M | $51M | |
| Liabilities + Equity | $240M | $36M | $45M | $52M | $94M | $143M | $168M | $215M | $129M | $42M | $48M | $57M | |
| Shares Outstanding | 27,556,767 | 1,018,604 | 64,393,744 | 54,377,798 | 52,313,894 | 49,017,622 | 43,466,933 | 43,160,751 | 34,359,799 | 23,250,023 | 19,050,204 | 18,939,838 |
Cashflow 11
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $13M | $5M | $4M | $4M | $6M | $7M | $6M | $5M | $4M | $3M | $2M | $2M | |
| Deferred Tax | $0 | · | · | · | · | · | · | · | · | · | · | · | |
| Restructuring | · | $7M | · | · | · | · | · | · | · | · | · | · | |
| Operating Cash Flow | $-72M | $-31M | $-35M | $-46M | $-57M | $-39M | $-52M | $-43M | $-30M | $-30M | $-8M | $-4M | |
| CapEx | $919.0K | $10.0K | $21.4K | $84.2K | $14.9K | $68.5K | $144.9K | $125.6K | $294.1K | $704.2K | $268.6K | $212.6K | |
| Investing Cash Flow | $-73M | $20.0K | $-21.4K | $-84.2K | $-14.9K | $-68.5K | $-144.9K | $-125.6K | $-294.1K | $-704.2K | $-268.6K | · | |
| Stock Issued | $0 | · | $29M | $4M | $11M | $18M | · | $128M | $114M | $24M | · | $57M | |
| Net Stock Activity | $0 | · | $29M | $4M | $11M | $18M | · | $128M | $114M | $24M | · | $57M | |
| Financing Cash Flow | $323M | $5.4K | $29M | $4M | $11M | $18M | $412.9K | $129M | $114M | $24M | $114.1K | · | |
| Net Change in Cash | $179M | $-31M | $-6M | $-42M | $-47M | $-21M | $-52M | $86M | $84M | $-7M | $-8M | $53M | |
| Free Cash Flow | $-72M | $-31M | $-35M | $-47M | $-58M | $-39M | $-52M | $-43M | $-30M | $-30M | $-9M | $-4M |
Rentabilität 7
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -1407.5% | · | -392752.9% | -63204.4% | -5470.7% | -506.8% | · | · | · | -172505.3% | -63.7% | -74.1% | |
| Net Margin | -1419.6% | · | -368994.2% | -62251.7% | -5469.0% | -502.1% | · | · | · | -171945.1% | -63.6% | -74.0% | |
| Pretax Margin | -1401.2% | · | · | · | · | · | · | · | · | · | · | · | |
| EBITDA Margin | -1407.5% | · | -392752.9% | -63204.4% | -5470.7% | -506.8% | · | · | · | -172505.3% | -63.7% | -74.1% | |
| ROA | -111.6% | -134.3% | -76.0% | -63.9% | -53.5% | -32.8% | -30.2% | -28.1% | -38.9% | -70.0% | -24.2% | -35.6% | |
| ROE | -90.0% | -1888.5% | -86.9% | -102.6% | -71.2% | -38.3% | -36.0% | -22.8% | -42.9% | -84.0% | -28.0% | -41.4% | |
| ROIC | -76.2% | · | · | · | · | · | · | · | · | · | · | · |
Liquidität & Solvenz 2
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 6.6 | 1.9 | 6.4 | 5.7 | 7.7 | 11.1 | 14.8 | 24.2 | 15.6 | 6.4 | 6.1 | 8.7 | |
| Quick Ratio | 6.4 | 1.9 | 6.1 | 5.4 | 7.6 | 11.0 | 14.4 | 24.0 | 15.2 | 6.3 | 6.0 | 8.5 |
Effizienz 2
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | · | 0.0 | 0.0 | 0.0 | 0.1 | · | · | · | 0.0 | 0.4 | 0.5 | |
| Receivables Turnover | 1.2 | · | · | · | · | · | · | · | · | · | · | · |
Wachstumsraten 3
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | · | · | -86.7% | -93.5% | -88.6% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 424.9% | · | -90.0% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 1.3% | · | · | · | · | · | · | · | · | · | · | · |
Bewertung (TTM) 10
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $11M | · | $10.0K | $75.0K | $1M | $10M | · | · | · | $18.5K | $20M | $15M | |
| Net Income TTM | $-154M | $-38M | $-37M | $-47M | $-63M | $-51M | $-58M | $-48M | $-33M | $-32M | $-13M | $-11M | |
| Market Cap | $327M | $1.61B | $15.20B | $16.48B | $7.53B | $18.43B | $22.99B | $40.87B | $57.69B | $14.18B | $10.90B | $13.64B | |
| P/E | -24.2 | -42.4 | -406.9 | -340.4 | -117.1 | -335.7 | -394.8 | -1262.7 | -2238.7 | -813.3 | -805.6 | -1200.0 | |
| P/S | 30.1 | · | 1519692.4 | 219686.3 | 6495.4 | 1813.5 | · | · | · | 766622.4 | 542.9 | 907.5 | |
| P/B | 1.6 | 303.4 | 395.6 | 383.8 | 92.3 | 143.7 | 149.1 | 198.9 | 481.9 | 401.8 | 269.2 | 268.4 | |
| P / Tangible Book | 1.6 | · | 395.6 | 383.8 | 92.3 | 143.7 | · | · | · | · | · | · | |
| P / Cash Flow | -4.6 | -51.8 | -435.7 | -354.7 | -131.0 | -469.7 | -442.3 | -943.3 | -1938.0 | -477.0 | -1322.1 | -3185.0 | |
| P / FCF | -4.5 | -51.8 | -435.4 | -354.0 | -131.0 | -468.8 | -441.1 | -940.5 | -1919.0 | -466.0 | -1280.4 | -3034.3 | |
| Earnings Yield | -4.1% | -2.4% | -0.25% | -0.29% | -0.85% | -0.30% | -0.25% | -0.08% | -0.04% | -0.12% | -0.12% | -0.08% |
Gewinn- und Verlustrechnung 13
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $1M | · | · | $0 | $0 | · | · | · | · | · | · | · | · | $0 | · | |
| R&D Expense | $19M | $18M | $106M | $20M | $12M | $11M | $233.2K | $2M | $6M | $6M | $5M | $5M | $4M | $5M | $6M | $5M | |
| SG&A Expense | $9M | $8M | $9M | $6M | $9M | $4M | $5M | $4M | $4M | $5M | $4M | $5M | $5M | $6M | $5M | $4M | |
| Operating Expenses | $28M | $26M | $114M | $26M | $21M | $14M | $7M | $11M | $10M | $11M | $10M | $10M | $9M | $11M | $11M | $9M | |
| Operating Income | $-26M | $-25M | $-103M | $-26M | $-21M | $-14M | $-7M | $-11M | $-10M | $-11M | $-10M | $-10M | $-9M | $-11M | $-11M | $-9M | |
| Other Non-op | $2M | $1M | · | $1M | $-760.0K | $-924.0K | $110.1K | $1M | · | · | $512.2K | $611.0K | · | · | · | · | |
| Income Tax | $0 | $0 | $2M | $0 | $0 | $0 | · | · | · | · | · | · | · | · | · | · | |
| Net Income | $-25M | $-23M | $-23M | $-25M | $-22M | $-15M | $-7M | $-10M | $-10M | $-11M | $-9M | $-9M | $-8M | $-10M | $-10M | $-9M | |
| EPS (Basic) | · | · | · | · | · | $-0.04 | $-0.11 | $-0.15 | $-0.16 | $-0.17 | $-0.14 | $-0.14 | $-0.13 | $-0.17 | $-0.20 | $-0.16 | |
| EPS (Diluted) | · | · | · | · | · | · | $-0.24 | $-0.15 | $-0.16 | $-0.04 | $-0.14 | $-0.14 | $-0.13 | $-0.17 | $-0.20 | $-0.16 | |
| Shares (Basic) | · | · | · | · | · | 64,522,257 | -128,947,790 | 64,483,958 | 64,483,848 | 64,457,233 | -125,633,555 | 64,349,709 | 64,276,184 | 60,350,127 | -104,631,509 | 52,423,944 | |
| Shares (Diluted) | · | · | · | · | · | · | -129,012,814 | 64,483,958 | 64,483,848 | 64,522,257 | -129,740,661 | 64,349,709 | 64,276,184 | 64,457,233 | -104,631,509 | 52,423,944 | |
| EBITDA | $-26M | · | · | $-26M | $-21M | $-2M | · | $-11M | $-10M | $-11M | · | $-10M | $-9M | $-11M | · | $-9M |
Bilanz 21
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $172M | $189M | $213M | $133M | $153M | $6M | $11M | $14M | $22M | $31M | $42M | $49M | $58M | $65M | $48M | $52M | |
| Receivables | $0 | $0 | $18M | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Prepaid Expense | $7M | $6M | $5M | $1M | $2M | $378.0K | $371.3K | $1M | $1M | $2M | $2M | $3M | $2M | $3M | $3M | $2M | |
| Other Current Assets | $7M | $6M | $5M | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Current Assets | $179M | $196M | $237M | $135M | $154M | $6M | $11M | $16M | $24M | $33M | $44M | $52M | $60M | $68M | $51M | $54M | |
| PP&E (Net) | $876.0K | $929.0K | $846.0K | $782.0K | $193.0K | · | · | · | · | · | · | $133.0K | $167.9K | $200.7K | · | $288.1K | |
| PP&E (Gross) | · | · | · | · | · | · | · | · | · | · | · | $3M | $3M | $3M | · | $3M | |
| Accum. Depreciation | · | · | · | · | · | · | · | · | · | · | · | $3M | $2M | $2M | · | $2M | |
| Other Non-current Assets | $1M | $1M | $1M | $1M | $1M | · | · | · | · | · | · | · | · | · | · | · | |
| Total Assets | $183M | $199M | $240M | $138M | $157M | $6M | $11M | $16M | $24M | $34M | $45M | $53M | $62M | $69M | $52M | $56M | |
| Accounts Payable | · | · | · | · | · | $104.7K | $329.3K | $581.8K | $950.8K | $755.5K | $868.1K | $329.9K | $241.5K | $480.2K | $970.2K | $852.1K | |
| Accrued Liabilities | $7M | $4M | $16M | $9M | $8M | $3M | $5M | $3M | $3M | $4M | $5M | $5M | $6M | $6M | $7M | $6M | |
| Current Liabilities | $19M | $14M | $36M | $20M | $17M | $3M | $6M | $4M | $4M | $5M | $7M | $6M | $7M | $7M | $9M | $8M | |
| Capital Leases | $966.0K | $1M | $1M | $1M | $1M | · | · | · | · | · | $66.8K | $262.1K | $448.8K | · | · | $95.6K | |
| Total Liabilities | $20M | $15M | $37M | $22M | $18M | $3M | $6M | $4M | $4M | $5M | $7M | $7M | $7M | $7M | $9M | $8M | |
| Common Stock | $28.0K | $28.0K | $28.0K | $14.0K | $14.0K | $64.5K | $64.5K | $64.5K | $64.5K | $64.5K | $64.4K | $64.4K | $64.3K | $64.2K | $54.4K | $52.4K | |
| Paid-in Capital | $379M | $375M | $371M | $192M | $190M | $500M | $500M | $498M | $497M | $496M | $495M | $494M | $493M | $492M | $462M | $457M | |
| Retained Earnings | $-220M | $-195M | $-172M | $-79M | $-55M | $-497M | $-494M | $-487M | $-477M | $-467M | $-456M | $-447M | $-438M | $-430M | $-420M | $-409M | |
| Stockholders' Equity | $163M | $184M | $203M | $117M | $139M | $3M | $5M | $11M | $20M | $29M | $38M | $47M | $55M | $62M | $43M | $48M | |
| Liabilities + Equity | $183M | $199M | $240M | $138M | $157M | $6M | $11M | $16M | $24M | $34M | $45M | $53M | $62M | $69M | $52M | $56M | |
| Shares Outstanding | 27,756,044 | 27,571,935 | 27,556,767 | 13,892,516 | 13,892,562 | 64,532,091 | 64,483,958 | 64,483,958 | 64,483,958 | 64,450,835 | 64,393,744 | 64,368,843 | 64,313,333 | 64,245,224 | 54,377,798 | 52,423,944 |
Cashflow 10
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $4M | $4M | $5M | $2M | $6M | $1M | $1M | $1M | $1M | $1M | $908.4K | $887.8K | $858.1K | $870.2K | $899.2K | $914.0K | |
| Restructuring | · | · | · | · | · | · | · | $5M | · | · | · | · | · | · | · | · | |
| Operating Cash Flow | $-19M | $-9M | $-27M | $-18M | $-22M | $-11M | $-4M | $-8M | $-9M | $-11M | $-8M | $-9M | $-7M | $-12M | $-8M | $-9M | |
| CapEx | $13.0K | $147.0K | $193.0K | $586.0K | $140.0K | $0 | $0 | $0 | $2.5K | $7.4K | $801 | $7.9K | $10.5K | $2.2K | $1 | $2.5K | |
| Investing Cash Flow | $2M | $-8M | $-72M | $-586.0K | $-140.0K | $0 | $30.0K | $0 | $-2.5K | $-7.4K | $-801 | $-7.9K | $-10.5K | $-2.2K | $-1 | $-2.5K | |
| Stock Issued | · | · | · | · | · | · | · | · | · | · | $0 | $0 | $0 | $29M | · | · | |
| Net Stock Activity | · | · | · | · | · | · | · | · | · | · | · | · | · | $29M | · | · | |
| Financing Cash Flow | $136.0K | $-7M | $179M | $-1M | $147M | $-1M | $0 | $0 | $500 | $4.9K | $999 | $61.6K | $20.1K | $29M | · | · | |
| Net Change in Cash | $-18M | $-24M | $80M | $-19M | $123M | $-12M | $-4M | $-8M | $-9M | $-11M | $-8M | $-9M | $-7M | $17M | $-4M | $-9M | |
| Free Cash Flow | · | · | · | · | · | · | · | · | · | $-11M | · | · | · | $-12M | · | · |
Rentabilität 2
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROA | -14.6% | · | · | -32.0% | -24.0% | -11.7% | · | -28.5% | -23.4% | -20.8% | · | -16.9% | -13.0% | -13.8% | · | -10.4% | |
| ROE | -16.4% | · | · | -38.4% | -27.4% | -14.5% | · | -33.9% | -27.0% | -23.6% | · | -19.4% | -14.9% | -15.9% | · | -11.8% |
Liquidität & Solvenz 2
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 9.7 | · | · | 6.6 | 9.2 | 2.3 | · | 3.6 | 5.5 | 6.3 | · | 8.1 | 9.2 | 10.1 | · | 6.9 | |
| Quick Ratio | 9.3 | · | · | 6.6 | 9.1 | 2.1 | · | 3.3 | 5.1 | 5.9 | · | 7.7 | 8.8 | 9.6 | · | 6.7 |
Effizienz 2
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Receivables Turnover | 0.0 | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
Bewertung (TTM) 8
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income TTM | $-96M | $-93M | · | $-71M | $-57M | $-46M | · | $-40M | $-38M | $-39M | · | $-36M | $-40M | $-47M | · | $-54M | |
| Market Cap | $500M | · | · | $165M | $224M | $1.36B | · | $1.10B | $1.81B | $19.34B | · | $9.66B | $11.19B | $8.09B | · | $2.88B | |
| P/E | -36.7 | -37.5 | · | -24.3 | -32.9 | -42.9 | · | -34.7 | -59.6 | -625.0 | · | -250.0 | -245.1 | -146.5 | · | -53.4 | |
| P/B | 3.1 | · | · | 1.4 | 1.6 | 401.5 | · | 96.4 | 90.0 | 668.8 | · | 207.4 | 204.2 | 130.2 | · | 59.9 | |
| P / Tangible Book | 3.1 | 2.8 | · | 1.4 | 1.6 | 401.5 | · | 96.4 | 90.0 | 668.8 | · | 207.4 | 204.2 | 130.2 | · | 59.9 | |
| P / Cash Flow | · | · | · | · | · | -265.4 | · | · | · | -1839.9 | · | · | · | -697.4 | · | · | |
| P / FCF | · | · | · | · | · | · | · | · | · | -1838.6 | · | · | · | -697.3 | · | · | |
| Earnings Yield | -2.7% | -2.7% | · | -4.1% | -3.0% | -2.3% | · | -2.9% | -1.7% | -0.16% | · | -0.40% | -0.41% | -0.68% | · | -1.9% |
Finanzberichte Gewinn- und Verlustrechnung, Bilanz, Cashflow — jährlich, letzte 5 Jahre
Gewinn- und Verlustrechnung
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Umsatz | $11M | — | $10.0K | $75.0K | $1M |
| Betriebsgewinnmarge % | -1407.5% | — | -392752.9% | -63204.4% | -5470.7% |
| Nettoergebnis | $-154M | $-38M | $-37M | $-47M | $-63M |
| Verwässerte EPS | — | $-0.59 | $-0.58 | $-0.89 | $-1.23 |
Bilanz
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Liquiditätsgrad | 6.6 | 1.9 | 6.4 | 5.7 | 7.7 |
| Quick Ratio | 6.4 | 1.9 | 6.1 | 5.4 | 7.6 |
Cashflow
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Freier Cashflow | $-72M | $-31M | $-35M | $-47M | $-58M |
Meine Kennzahlen Ihre persönliche Watchlist — ausgewählte Zeilen aus den vollständigen Fundamentaldaten
📊
Wählen Sie die Kennzahlen, die für Sie wichtig sind — klicken Sie auf das ➕ neben jeder Zeile in den vollständigen Fundamentaldaten oben.
Ihre Auswahl wird gespeichert und begleitet Sie über alle Ticker hinweg.
Institutionelle Eigentümer (13F) 82 Einreicher · $470.5M gesamt · Stand 30. Juni 2026
Institutionen, die diese Aktie in ihrer vierteljährlichen SEC-Formular 13F melden. Nur Long-Positionen; ein einzelner Einreicher kann für separate Optionsscheine zweimal erscheinen. Große gegenläufige Put/Call-Positionen spiegeln typischerweise Market-Making oder abgesicherte Bestände wider, nicht die gerichtete Überzeugung.
Institutionelle Aktivität — Q2 2026 vs. Vorquartal
| Neue Positionen | Geschlossene Positionen | Erhöht | Abgenommen | Nettoveränderung der Aktien |
|---|---|---|---|---|
| 35 (+21 vs. Vorquartal) | 12 (+2 vs. Vorquartal) | 14 (-3 vs. Vorquartal) | 15 (+7 vs. Vorquartal) | +3.5M |
Verglichen mit Q1 2026. SEC-Formular 13F-Einreichungen sind innerhalb von 45 Tagen nach Quartalsende fällig, zuzüglich einer kurzen Pufferzeit für verspätete Einreicher — Quartale, die noch in diesem Fenster liegen, werden zugunsten des letzten vollständig berichteten Paares übersprungen.
| Institution | Wert | Aktien | % der verfolgten 13F | Typ |
|---|---|---|---|---|
| FMR LLC | $51.011.496 | 2.833.972 | 10,84% | Aktien |
| BVF INC/IL | $49.477.734 | 2.748.763 | 10,52% | Aktien |
| Fairmount Funds Management LLC | $49.461.588 | 2.747.866 | 10,51% | Aktien |
| Venrock Adviser, LLC | $38.404.368 | 2.133.576 | 8,16% | Aktien |
| Logos Global Management LP | $34.200.000 | 1.900.000 | 7,27% | Aktien |
| FCPM III SERVICES B.V. | $30.201.336 | 1.677.852 | 6,42% | Aktien |
| Balyasny Asset Management L.P. | $29.932.506 | 1.662.917 | 6,36% | Aktien |
| Vestal Point Capital, LP | $29.340.000 | 1.630.000 | 6,24% | Aktien |
| Opaleye Management Inc. | $23.748.318 | 1.319.351 | 5,05% | Aktien |
| TANG CAPITAL MANAGEMENT LLC | $20.880.000 | 1.160.000 | 4,44% | Aktien |
| VANGUARD CAPITAL MANAGEMENT LLC | $13.819.590 | 767.755 | 2,94% | Aktien |
| MILLENNIUM MANAGEMENT LLC | $7.269.462 | 403.859 | 1,55% | Aktien |
| JENNISON ASSOCIATES LLC | $6.813.126 | 378.507 | 1,45% | Aktien |
| RTW INVESTMENTS, LP | $6.711.408 | 372.856 | 1,43% | Aktien |
| NEXTBio Capital Management LP | $6.711.408 | 372.856 | 1,43% | Aktien |
| Remedium Capital Partners, LLC | $6.502.500 | 361.250 | 1,38% | Aktien |
| GEODE CAPITAL MANAGEMENT, LLC | $6.056.873 | 336.411 | 1,29% | Aktien |
| VANGUARD GROUP INC | $5.984.722 | 504.614 | 1,27% | Aktien |
| STATE STREET CORP | $5.680.566 | 315.587 | 1,21% | Aktien |
| AMERIPRISE FINANCIAL INC | $5.446.224 | 302.568 | 1,16% | Aktien |
| Point72 Asset Management, L.P. | $5.400.000 | 300.000 | 1,15% | Aktien |
| PERCEPTIVE ADVISORS LLC | $3.724.956 | 206.942 | 0,79% | Aktien |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $3.398.454 | 188.803 | 0,72% | Aktien |
| TWO SIGMA INVESTMENTS, LP | $3.363.732 | 186.874 | 0,71% | Aktien |
| STEMPOINT CAPITAL LP | $3.282.876 | 182.382 | 0,70% | Aktien |
| UBS Group AG | $3.061.674 | 170.093 | 0,65% | Aktien |
| Exome Asset Management LLC | $2.299.842 | 127.769 | 0,49% | Aktien |
| SECTORAL ASSET MANAGEMENT INC | $2.183.400 | 121.300 | 0,46% | Aktien |
| Woodline Partners LP | $1.700.784 | 94.488 | 0,36% | Aktien |
| VANGUARD FIDUCIARY TRUST CO | $1.354.050 | 75.225 | 0,29% | Aktien |
| Burkehill Global Management, LP | $1.332.000 | 74.000 | 0,28% | Aktien |
| Blackstone Inc. | $1.127.646 | 62.647 | 0,24% | Aktien |
| SILVERARC CAPITAL MANAGEMENT, LLC | $1.063.872 | 59.104 | 0,23% | Aktien |
| Y-Intercept (Hong Kong) Ltd | $914.832 | 50.824 | 0,19% | Aktien |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $904.644 | 50.258 | 0,19% | Aktien |
| Nuveen, LLC | $857.322 | 47.629 | 0,18% | Aktien |
| Stonepine Capital Management, LLC | $720.000 | 40.000 | 0,15% | Aktien |
| RHUMBLINE ADVISERS | $458.766 | 25.487 | 0,10% | Aktien |
| MOORE CAPITAL MANAGEMENT, LP | $450.000 | 25.000 | 0,10% | Aktien |
| Squarepoint Ops LLC | $434.988 | 24.166 | 0,09% | Aktien |
| AMERICAN CENTURY COMPANIES INC | $410.490 | 22.805 | 0,09% | Aktien |
| TWO SIGMA ADVISERS, LP | $385.450 | 32.500 | 0,08% | Aktien |
| WELLS FARGO & COMPANY/MN | $354.600 | 19.700 | 0,08% | Aktien |
| ADAR1 Capital Management, LLC | $328.950 | 18.275 | 0,07% | Aktien |
| Virtus Investment Advisers, LLC | $328.644 | 18.258 | 0,07% | Aktien |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $319.590 | 17.755 | 0,07% | Aktien |
| BANK OF MONTREAL /CAN/ | $247.806 | 13.767 | 0,05% | Aktien |
| MetLife Investment Management, LLC | $230.040 | 12.780 | 0,05% | Aktien |
| Bank of New York Mellon Corp | $224.892 | 12.494 | 0,05% | Aktien |
| BANK OF AMERICA CORP /DE/ | $223.452 | 12.414 | 0,05% | Aktien |
| Persistent Asset Partners Ltd | $197.424 | 10.968 | 0,04% | Aktien |
| XTX Topco Ltd | $190.152 | 10.564 | 0,04% | Aktien |
| MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | $178.218 | 9.901 | 0,04% | Aktien |
| CITIGROUP INC | $160.110 | 8.895 | 0,03% | Aktien |
| Invesco Ltd. | $154.980 | 8.610 | 0,03% | Aktien |
| NEW YORK STATE COMMON RETIREMENT FUND | $136.800 | 7.600 | 0,03% | Aktien |
| BlackRock, Inc. | $119.484 | 6.638 | 0,03% | Aktien |
| Police & Firemen's Retirement System of New Jersey | $114.642 | 6.369 | 0,02% | Aktien |
| WELLINGTON MANAGEMENT GROUP LLP | $84.600 | 4.700 | 0,02% | Aktien |
| NORTHERN TRUST CORP | $61.128 | 3.396 | 0,01% | Aktien |
| BNP PARIBAS FINANCIAL MARKETS | $59.454 | 3.303 | 0,01% | Aktien |
| MARSHALL WACE, LLP | $59.130 | 3.285 | 0,01% | Aktien |
| BARCLAYS PLC | $54.648 | 3.036 | 0,01% | Aktien |
| Vanguard Global Advisers, LLC | $48.852 | 2.714 | 0,01% | Aktien |
| Legal & General Group Plc | $37.746 | 2.097 | 0,01% | Aktien |
| Tower Research Capital LLC (TRC) | $31.500 | 1.750 | 0,01% | Aktien |
| Russell Investments Group, Ltd. | $31.068 | 1.726 | 0,01% | Aktien |
| ROYAL BANK OF CANADA | $12.000 | 661 | 0,00% | Aktien |
| US BANCORP \DE\ | $7.254 | 403 | 0,00% | Aktien |
| Parallel Advisors, LLC | $4.752 | 264 | 0,00% | Aktien |
| PRICE T ROWE ASSOCIATES INC /MD/ | $4.488 | 249.312 | 0,00% | Aktien |
| Allworth Financial LP | $2.898 | 161 | 0,00% | Aktien |
| Sterling Capital Management LLC | $1.368 | 76 | 0,00% | Aktien |
| SBI Securities Co., Ltd. | $1.224 | 68 | 0,00% | Aktien |
| JPMORGAN CHASE & CO | $1.206 | 67 | 0,00% | Aktien |
| MERCER GLOBAL ADVISORS INC /ADV | $900 | 50 | 0,00% | Aktien |
| MORGAN STANLEY | $792 | 44 | 0,00% | Aktien |
| Fortitude Family Office, LLC | $720 | 40 | 0,00% | Aktien |
| Quarry LP | $522 | 29 | 0,00% | Aktien |
| OSAIC HOLDINGS, INC. | $468 | 26 | 0,00% | Aktien |
| Caitong International Asset Management Co., Ltd | $378 | 21 | 0,00% | Aktien |
| NATIONAL BANK OF CANADA /FI/ | $54 | 3 | 0,00% | Aktien |
Unternehmensinsider 33 Insider · 15 Führungskräfte · 18 Direktoren
| Insider | Rolle | Letzte Aktivität | Gehaltene Aktien | Käufe 12m | Verkäufe 12m | Netto 12m |
|---|---|---|---|---|---|---|
| Joshua T Brumm | Chief Executive Officer | 22. Juni 2026 S | 281.212 | 0 | 1 | $-761.067 |
| Harout Semerjian | Chief Executive Officer | 12. Januar 2024 A | 25.000 | 0 | 0 | $0 |
| Richard William Scalzo | Chief Financial Officer | 22. Juni 2026 S | 20.298 | 0 | 1 | $-20.005 |
| Brian M. Hahn | SVP Finance, CFO | 12. Januar 2024 A | 53.143 | 0 | 0 | $0 |
| Jonathan Mcneill | President and COO | 22. Juni 2026 S | 139.158 | 0 | 1 | $-369.677 |
| Jan Pinkas | Chief Scientific Officer | 22. Juni 2026 S | 22.239 | 0 | 1 | $-23.171 |
| Barbara Harlin Bispham | General Counsel and Corporate Secretary. | 22. Juni 2026 S | 19.330 | 0 | 1 | $-21.912 |
| Ellie Eunkyung Im | Chief Medical Officer | 22. Juni 2026 S | 22.069 | 0 | 1 | $-21.930 |
| Ryan Lynch | Treasurer, Senior Vice President of Finance and Chief Accounting Officer. | 22. Juni 2026 S | 13.871 | 0 | 1 | $-8.365 |
| Bruce S Johnson | SVP & Chief Commercial Officer | 12. Januar 2024 A | 138.980 | 0 | 0 | $0 |
| Chinmaya Rath | SVP and Chief Business Officer | 12. Januar 2024 A | — | 0 | 0 | $0 |
| Edwin Rock | Chief Medical Officer | 12. Januar 2024 A | 375.403 | 0 | 0 | $0 |
| Armand Girard | SVP, Chief Business Officer | 11. November 2022 P | 29.161 | 0 | 0 | $0 |
| John L. Magnani | SVP of Research, CSO | 11. November 2022 P | 366.078 | 0 | 0 | $0 |
| Helen M. Thackray | SVP Clinical Development, CMO | 20. Januar 2021 A | 183.115 | 0 | 0 | $0 |
| Alexandra Balcom | Direktor | 2. Juni 2026 A | — | 0 | 0 | $0 |
| Susan Moran | Direktor | 2. Juni 2026 A | — | 0 | 0 | $0 |
| Jonathan Violin | Direktor | 2. Juni 2026 A | — | 0 | 0 | $0 |
| David Charles Lubner | Direktor | 2. Juni 2026 A | — | 0 | 0 | $0 |
| Rachel K. King | Direktor | 29. Dezember 2023 A | 511.860 | 0 | 0 | $0 |
| Mark Alan Goldberg | Direktor | 29. Dezember 2023 A | 20.244 | 0 | 0 | $0 |
| Patricia S Andrews | Direktor | 29. Dezember 2023 A | 58.608 | 0 | 0 | $0 |
| Scott Koenig | Direktor | 1. Juni 2023 M | 36.750 | 0 | 0 | $0 |
| Scott Thomas Jackson | Direktor | 19. Mai 2023 A | 5.250 | 0 | 0 | $0 |
| Timothy R Pearson | Direktor | 19. Mai 2023 A | 24.650 | 0 | 0 | $0 |
| JUNIUS DANIEL M | Direktor | 19. Mai 2023 A | 93.250 | 0 | 0 | $0 |
| James M Barrett | Direktor | 18. Mai 2018 A | 4.995.664 | 0 | 0 | $0 |
| John J. Baldwin | Direktor | 29. Juni 2016 M | 1.210 | 0 | 0 | $0 |
| Franklin H Top JR | Direktor | 17. Mai 2016 A | 12.294 | 0 | 0 | $0 |
| Michael A Henos | Direktor | 15. Juli 2015 A | 469.454 | 0 | 0 | $0 |
| William M. Gust | Direktor | 15. Januar 2014 C | 409.947 | 0 | 0 | $0 |
| Scott D. Sandell | 10%-Eigentümer | 26. Januar 2023 S | 2.237.196 | 0 | 0 | $0 |
| Peter J Barris | 10%-Eigentümer | 10. Mai 2018 X | 4.995.664 | 0 | 0 | $0 |
Insider aus SEC-Einreichungen Form 3/4/5; Netto = nur P/S aus offenen Märkten
Aktivisten & 5%+-Eigentümer 4 Beteiligungen
Investoren mit SEC Schedule 13D — wirtschaftliches Eigentum über 5% mit der Absicht, Einfluss auf den Emittenten zu nehmen (aktivistische Beteiligungen, Board-Kampagnen, M&A). Jede Zeile zeigt den zuletzt bekannten Stand der Position dieses Melders.
| Anmelder | Eingereicht | Beteiligung | Status | Zweck | Einreichung |
|---|---|---|---|---|---|
| Fairmount Funds Management LLC, Fairmount Healthcare Fund II L.P., Peter Harwin, Tomas Kiselak ×3 Einreichungen | 20. Juli 2026 | 16,52% | Änderung | Passive Anlage | SEC |
| Adage Capital Management, L.P., Robert Atchinson, Phillip Gross ×2 Einreichungen | 20. Juni 2025 | 0,37% | Änderung | — | SEC |
| 8. Mai 2024 | — | Erste Einreichung | — | SEC | |
| New Enterprise Associates 10, Limited Partnership, NEA Partners 10, Limited Partnership, New Enterprise Associates 13, L.P., NEA Partners 13, L.P., NEA 13 GP, LTD, Anthony A. Florence, Jr, Mohamad H. Makhzoumi, Scott D. Sandell ×4 Einreichungen | 29. Februar 2024 | — | Erste Einreichung | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
ETF-Besitz Gehalten von 10 ETFs
Gewichtung spiegelt nur direkte Aktienbestände (N-PORT) wider; gehebelte oder derivatbasierte Fonds können zusätzliche Swap-Exposure halten, die hier nicht angezeigt wird.
| Fonds | Gewicht | Anteile | Stand | Quelle |
|---|---|---|---|---|
| IWC · iShares Trust | 0,08% | 73.362 SH | 8. August 2026 | Täglich |
| IWO · iShares Trust | 0,02% | 197.875 SH | 8. August 2026 | Täglich |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,02% | 23.282 SH | 8. August 2026 | Täglich |
| AVSC · AMERICAN CENTURY ETF TRUST | 0,01% | 15.612 NS | 31. Mai 2026 | N-PORT |
| IWM · iShares Trust | 0,01% | 529.441 SH | 8. August 2026 | Täglich |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,01% | 124.281 SH | 8. August 2026 | Täglich |
| VXF · VANGUARD INDEX FUNDS | 0,00% | 83.801 SH | 8. August 2026 | Täglich |
| VTI · VANGUARD INDEX FUNDS | 0,00% | 661.946 SH | 8. August 2026 | Täglich |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,00% | 1.832 SH | 8. August 2026 | Täglich |
| VHT · VANGUARD WORLD FUND | 0,00% | 39.408 SH | 8. August 2026 | Täglich |